Massachusetts offers more low-price Rx plans

30 April 2001

Several bills to introduce more low-income residents of the US state ofMassachusetts to low-cost drugs have been introduced. One would monitor the cost of drugs and report on firms that overcharge consumers, while another would give low-income children in the state-funded health insurance program pharmacy benefits.

Another would let county, city and town municipal staff buy drugs at the prices paid by members of the Group Insurance Commission, which manages health insurance benefits for 263,000 state workers and their families. A fourth would create a commission to determine if drug prices are reasonable, identify firms that overcharge and publicize the amount they spend on marketing and promotions, said Secretary of State William Galvin, who would chair such a panel, and who added that this bill would not be costly to implement, reports the Associated Press.

Massachusetts has begun to sign up seniors and the disabled for its pioneering Prescription Advantage drug insurance program, the first US insurance-based plan and, to date, about 23,000 have joined. Monthly premiums range from nothing for the poorest to $82 for those earning $42,961 or more a year. In addition, lawmakers are seeking ways to help more low-income residents get access to drugs and at lower costs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight